Icure Pharmaceutical's Total Assets for the quarter that ended in Dec. 2024 was ₩132,883 Mil.
During the past 12 months, Icure Pharmaceutical's average Total Assets Growth Rate was -29.90% per year.
During the past 3 years, the average Total Assets Growth Rate was -16.70% per year.
During the past 5 years, the average Total Assets Growth Rate was -7.80% per year.
During the past 10 years, the average Total Assets Growth Rate was 31.20% per year.
During the past 11 years, Icure Pharmaceutical's highest 3-Year average Total Assets Growth Rate was 80.50%. The lowest was -16.70%. And the median was 45.25%.
The historical data trend for Icure Pharmaceutical's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Icure Pharmaceutical's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Icure Pharmaceutical (XKRX:175250) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Icure Pharmaceutical's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Icure Pharmaceutical Total Assets Related Terms
Thank you for viewing the detailed overview of Icure Pharmaceutical's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Icure Pharmaceutical Inc operates as a biopharmaceutical company engages in the development and commercialization of novel transdermal drug delivery formulation. It also developed and commercialized various patches and hydrogels for the treatment of rheumatic arthritis pain, nicotine replacement therapy, medicated wound dressings, skin care, and dental care. The products pipeline is also aimed at the development of prescription drugs to diseases of the central nervous system, asthma, and pain.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:175250 has been successfully added to your 